MANGOCEUTICALS, INC. Reports Unregistered Equity Sale
Ticker: MGRX · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $25,000,000, $2.36, $78,787, $2.358 |
| Sentiment | neutral |
Sentiment: neutral
Topics: unregistered-sale, equity-securities, sec-filing
TL;DR
MANGOCEUTICALS sold unregistered equity. SEC filing out.
AI Summary
On October 18, 2024, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The company, incorporated in Texas with its principal executive offices in Dallas, filed a Form 8-K to disclose this event.
Why It Matters
This filing indicates a transaction involving the company's stock that was not registered with the SEC, which could have implications for investors and regulatory compliance.
Risk Assessment
Risk Level: medium — Unregistered sales can sometimes indicate potential regulatory issues or dilution concerns for existing shareholders.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- October 18, 2024 (date) — Date of Earliest Event Reported
- Texas (state) — State of Incorporation
- Dallas (city) — Principal Executive Offices Location
- 15110 N. Dallas Parkway , Suite 600 (address) — Principal Executive Offices Address
- 75248 (zip_code) — Principal Executive Offices Zip Code
- (214) 242-9619 (phone_number) — Registrant's telephone number
FAQ
What type of equity securities were sold in the unregistered offering?
The filing does not specify the exact type of equity securities sold, only that it was an unregistered sale of equity securities.
Were there any specific dollar amounts associated with this unregistered sale?
The provided text of the filing does not contain specific dollar amounts related to the unregistered sale of equity securities.
Who were the purchasers of these unregistered equity securities?
The filing does not disclose the identity of the purchasers of the unregistered equity securities.
What is the reason for conducting an unregistered sale of equity securities?
The filing does not provide a reason or justification for the unregistered sale of equity securities.
Does this unregistered sale require any future filings or actions from MANGOCEUTICALS, INC.?
The filing itself is the report of the event; further actions or filings would depend on the specific terms of the sale and regulatory requirements, which are not detailed here.
Filing Stats: 1,026 words · 4 min read · ~3 pages · Grade level 14.5 · Accepted 2024-10-25 17:00:28
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $25,000,000 — e Purchaser committed to purchase up to $25,000,000 of the Company's common stock pursuant
- $2.36 — k pursuant to the terms of the ELOC for $2.36 per share for a total of $78,787, net o
- $78,787 — ELOC for $2.36 per share for a total of $78,787, net of fees, discounts and expenses.
- $2.358 — ferred Stock. The shares were valued at $2.358 per share for a total value of $220,000
- $220,000 — t $2.358 per share for a total value of $220,000. The resale of the shares of common s
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-24-042546.txt ( ) — 214KB
- mgrx-20241018.xsd (EX-101.SCH) — 3KB
- mgrx-20241018_lab.xml (EX-101.LAB) — 33KB
- mgrx-20241018_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: October 25, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer